Interleukin-6 in pregnancy with sickle cell disease

Costa, Manuela; Torres, Leuridan Cavalcante; Matta, Marina Cadena da; Araújo, Aderson da Silva; Souza, Ariani Impieri de

doi:10.1016/j.htct.2019.02.001

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2,5,6 Notably, physiologic alter-ations in pregnancy can exacerbate the pathophysiologic state of SCD. 7,8 Moreover, complement activity and a subset of inflammatory monocytes may increase during pregnancy, 9 potentially increasing hyperhemolysis risk.…”

Section: Voxelotormentioning

confidence: 99%

Pregnant patients with sickle cell disease and hyperhemolysis requiring intrauterine transfusion: A challenging clinical scenario

Abels

Binns

Sostin

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Section: Voxelotormentioning

confidence: 99%

Pregnant patients with sickle cell disease and hyperhemolysis requiring intrauterine transfusion: A challenging clinical scenario

Abels

Binns

Sostin

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

“…Anemia severity is related to the type of SCD (homozygous or compound heterozygous). SCD is associated with inflammation, with high Il-6 concentrations [128]. As Il-6 increases hepcidin transcription via signal transducer and activator of transcription 3 (STAT3) [129,130], this mechanism is likely responsible for low iron concentrations and contributes to the anemia observed during SCD [46,131].…”

Section: Sickle-cell Diseasementioning

confidence: 99%

Iron Metabolism in Normal and Pathological Pregnancies and Fetal Consequences

et al. 2022

View full text Add to dashboard Cite

Iron is required for energy production, DNA synthesis, and cell proliferation, mainly as a component of the prosthetic group in hemoproteins and as part of iron-sulfur clusters. Iron is also a critical component of hemoglobin and plays an important role in oxygen delivery. Imbalances in iron metabolism negatively affect these vital functions. As the crucial barrier between the fetus and the mother, the placenta plays a pivotal role in iron metabolism during pregnancy. Iron deficiency affects 1.2 billion individuals worldwide. Pregnant women are at high risk of developing or worsening iron deficiency. On the contrary, in frequent hemoglobin diseases, such as sickle-cell disease and thalassemia, iron overload is observed. Both iron deficiency and iron overload can affect neonatal development. This review aims to provide an update on our current knowledge on iron and heme metabolism in normal and pathological pregnancies. The main molecular actors in human placental iron metabolism are described, focusing on the impact of iron deficiency and hemoglobin diseases on the placenta, together with normal metabolism. Then, we discuss data concerning iron metabolism in frequent pathological pregnancies to complete the picture, focusing on the most frequent diseases.

show abstract